1. Articles in category: Human Interest

    1-24 of 96 1 2 3 4 »
    1. Clinical manifestations of neuroblastoma with head and neck involvement in children.

      Clinical manifestations of neuroblastoma with head and neck involvement in children.

      Int J Pediatr Otorhinolaryngol. 2017 Jun;97:157-162

      Authors: Alvi S, Karadaghy O, Manalang M, Weatherly R

      Abstract OBJECTIVE: The purpose of our study is to review our 15-year experience with pediatric patients who have been diagnosed with neuroblastoma, and to determine their most frequent head and neck manifestations and symptoms. STUDY DESIGN: Retrospective chart review of electronic medical record.

      Read Full Article
    2. A single center clinical analysis of children with high-risk neuroblastoma.

      A single center clinical analysis of children with high-risk neuroblastoma.

      Oncotarget. 2017 Mar 07;:

      Authors: Tian X, Cao Y, Wang J, Yan J, Tian Y, Li Z, Wang H, Duan X, Jin Y, Zhao Q

      Abstract The current multidisciplinary treatment for patients with high-risk neuroblastoma (NB) is the common census. However, protocols and opinions are different in different regions and institutions.

      Read Full Article
      Mentions: Treatment LDH
    3. Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Pediatr Res. 2017 Apr 18;:

      Authors: Duong C, Yoshida S, Chen C, Barisone G, Diaz E, Li Y, Beckett L, Chung J, Antony R, Nolta J, Nitin N, Satake N

      Abstract BACKGROUND: Neuroblastoma is the second most common extracranial cancer in children.

      Read Full Article
    4. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

      Prior studies suggest that neuroblastomas that do not accumulate metaiodobenzylguanidine (MIBG) on diagnostic imaging (MIBG non-avid) may have more favorable features compared with MIBG avid tumors. We compared clinical features, biologic features, and clinical outcomes between patients with MIBG nonavid and MIBG avid neuroblastoma.

      Read Full Article
      Mentions: COG Imaging MYCN
    5. Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Jpn J Clin Oncol. 2016 Jul;46(7):661-6

      Authors: Iehara T, Yagyu S, Tsuchiya K, Kuwahara Y, Miyachi M, Tajiri T, Sugimoto T, Sawada T, Hosoi H

      Abstract BACKGROUND: It remains unclear whether a residual tumor mass following therapy influences the prognosis of neuroblastoma.

      Read Full Article
      Mentions: MIBG
    6. Study finds more childhood cancer survivors would likely benefit from genetic screening

      Study finds more childhood cancer survivors would likely benefit from genetic screening

      WASHINGTON, April 3, 2017 /PRNewswire/ -- Twelve percent of childhood cancer survivors carry germline mutations that put them or their children at increased risk of developing cancer, according to a landmark study presented today at the annual meeting of the American Association for...

      Read Full Article
    7. The importance of oncologists giving hope

      Previous article in Early View: Impact of shared care program in follow-up of childhood cancer survivors: An intervention study

      Previous article in Early View: Impact of shared care program in follow-up of childhood cancer survivors: An intervention study

      Next article in Early View: Infectious complications in children with acute lymphoblastic leukemia treated with the Taiwan Pediatric Oncology Group protocol: A 16-year tertiary single-institution experience

      Read Full Article
    8. ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      Scientists from The Institute of Cancer Research, London, have been awarded £1.5 million by the charity Children with Cancer UK to advance precision medicine in the UK and improve cancer treatment for children and young adults.

      Read Full Article
      Mentions: Treatment
    9. The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.

      The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.

      Aging (Albany NY). 2017 Mar 08;:

      Authors: He J, Wang F, Zhu J, Zhang Z, Zou Y, Zhang R, Yang T, Xia H

      Abstract TP53, a tumor suppressor gene, plays a critical role in cell cycle control, apoptosis, and DNA damage repair. Previous studies have indicated that the TP53 gene Arg72Pro (rs1042522 C>G) polymorphism is associated with susceptibility to various types of cancer.

      Read Full Article
    10. Advances in emerging drugs for the treatment of neuroblastoma.

      Advances in emerging drugs for the treatment of neuroblastoma.

      Expert Opin Emerg Drugs. 2017 Mar;22(1):63-75

      Authors: Berlanga P, Cañete A, Castel V

      Abstract INTRODUCTION: Neuroblastoma is the most common solid extracranial tumor of childhood. Outcome for children with high-risk neuroblastoma remains suboptimal. More than half of children diagnosed with high-risk neuroblastoma either do not respond to conventional therapies or relapse after treatment with dismal prognosis.

      Read Full Article
      Mentions: Treatment Relapse ALK
    11. Lin BioScience Licenses a Novel Anti-Cancer Therapy for Hematological Malignancies and Solid Tumors from Columbia University and Memorial Sloan Kettering Cancer Center

      Lin BioScience Licenses a Novel Anti-Cancer Therapy for Hematological Malignancies and Solid Tumors from Columbia University and Memorial Sloan Kettering Cancer Center

      SAN DIEGO, March 3, 2017 /PRNewswire/ -- Lin BioScience has licensed the intellectual property portfolio for a novel inhibitor of CDC7 kinase. Under this worldwide exclusive licensing agreement with Columbia University and Memorial Sloan Kettering Cancer Center, Lin BioScience plans to...

      Read Full Article
    12. Traditional and complementary medicine used with curative intent in childhood cancer: A systematic review.

      Traditional and complementary medicine used with curative intent in childhood cancer: A systematic review.

      Pediatr Blood Cancer. 2017 Feb 28;:

      Authors: Diorio C, Salena K, Ladas EJ, Lam CG, Afungcwhi GM, Njuguna F, Marjerrison S

      Abstract Traditional and complementary medicine (T&CM) strategies are widely utilized in pediatric oncology, with many families reporting T&CM use with the intention to cure cancer.

      Read Full Article
    13. Traditional and complementary medicine used with curative intent in childhood cancer: A systematic review

      Traditional and complementary medicine (T&CM) strategies are widely utilized in pediatric oncology, with many families reporting T&CM use with the intention to cure cancer. Study of T&CM agents presents many challenges, as a heterogeneous group of agents and techniques are used for a variety of different purpose in many different oncologic conditions. We present a systematic review of the literature examining published reports in which T&CM agents are used with an intention of cure.

      Read Full Article
    14. Risk factors and surveillance for reduced bone mineral density in pediatric cancer survivors.

      Risk factors and surveillance for reduced bone mineral density in pediatric cancer survivors.

      Pediatr Blood Cancer. 2017 Feb 24;:

      Authors: Siegel DA, Claridy M, Mertens A, George E, Vangile K, Simoneaux SF, Meacham LR, Wasilewski-Masker K

      Abstract BACKGROUND: Pediatric cancer survivors are at increased risk of developing low bone mineral density (BMD) due to cancer treatment.

      Read Full Article
      Mentions: Treatment COG
    15. Pregnancy in survivors of childhood cancer may confer elevated risk for cardiotoxicity

      Pregnancy may be linked to an increased risk for cardiotoxicity in patients who survived cancer in childhood, according to a research letter published in the Journal of the American College of Cardiology.Using data from The University of Texas MD Anderson Cancer Center, Kara A. Thompson, MD, from the department of cardiology at the University of Texas, Houston, and colleagues evaluated the cardiac outcomes of childhood cancer survivors who were pregnant and who were previously exposed to anthracyclines and/or chest radiation.

      Read Full Article
    16. Prominent Pulmonary Metastases Without Concurrent Osseous Involvement in Patients With High-Risk Neuroblastoma.

      Prominent Pulmonary Metastases Without Concurrent Osseous Involvement in Patients With High-Risk Neuroblastoma.

      Clin Nucl Med. 2017 Feb 13;:

      Authors: Bai X, Zhuang H

      Abstract Metastases from high-risk neuroblastomas generally are to the bone or bone marrow. Multiple lung metastases are rare, especially when there was no concurrent osseous metastasis. We report 2 cases of high-risk neuroblastomas having prominent lung metastases without concurrent osseous lesion observed.

      Read Full Article
    17. Overview and recent advances in the treatment of neuroblastoma.

      Overview and recent advances in the treatment of neuroblastoma.

      Expert Rev Anticancer Ther. 2017 Feb 01;:

      Authors: Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE

      Abstract INTRODUCTION: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease.

      Read Full Article
      Mentions: Treatment
    18. Respiratory Difficulties in Children With Underlying Asthma During Immunotherapy for High-risk Neuroblastoma.

      Respiratory Difficulties in Children With Underlying Asthma During Immunotherapy for High-risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jan 24;:

      Authors: Metrock LK, Qayed M, Simon D, Cash T, O'Connor MG, Johnson S, Esiashvili N, Katzenstein HM

      Abstract Treatment of high-risk neuroblastoma now includes antibody based antitumor immunotherapy as part of standard care.

      Read Full Article
    1-24 of 96 1 2 3 4 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles